Clinilabs Drug Development Corporation and Verified Clinical Trials (VCT) are pleased to announce the launch of Assure Screen, a pre-screening program for clinical trial participants that helps to reduce screen failure rates and the costs associated with screening study candidates. The Assure Screen program enables investigators to obtain informed consent from subjects to participate in a multicenter pre-screening program that allows the investigator to obtain medical history, vitals, height, weight, body mass index, concurrent illness, and concomitant medication data. These data are used to determine if a subject is eligible to screen for a sponsor-specific study. Using this method, the screen failure rate for sponsor-specific studies is reduced. Costs are contained for the sponsor by reducing the number of subjects screened, and for the site by allowed for better resource management. One of the nicest features of the program is that all information collected from Assure Screen participants is entered into VCT’s platform. Consequently, investigators are automatically provided with the subject profiles obtained from all prior pre-screening assessments whenever they use VCT as part of the subject selection process. This dramatically improves the quality of the subjects admitted to clinical trials.
